Abstract | BACKGROUND:
Fingolimod ( FTY720) is an immunomodulating drug that inhibits sphingosine-1-phosphate binding and blocks T-cell egress from lymph nodes. We analyzed the effect of FTY720 on the autoimmune T- and B-cell response in autoimmune arthritis and studied the mechanisms by which it alters the function of T cells. METHODS:
Human leukocyte antigen (HLA)-DR1 humanized mice were immunized with type II collagen (CII) and treated with FTY720 three times per week for 3 weeks. Arthritis was evaluated and autoimmune T- and B-cell responses were measured using proliferation assays, enzyme-linked immunosorbent assays, HLA-DR tetramers, and flow cytometry. The functional capacity of regulatory T (Treg) cells from FTY720-treated mice was measured using an in vitro suppression assay, and the role of Treg cells in inhibiting arthritis in FTY720-treated mice was evaluated using mice treated with anti-CD25 to deplete Treg cells. RESULTS: Treatment with FTY720 delayed the onset of arthritis and significantly reduced disease incidence. FTY720 did not prevent the generation of a CII-specific autoimmune T-cell response in vivo. However, as the treatment continued, these T cells became unresponsive to restimulation with antigen in vitro, and this anergic state was reversed by addition of interleukin 2. Measurements of CD4(+)CD25(+)Foxp3(+) cells in the lymph nodes revealed that the ratio of Treg to helper T (Th) cells increased twofold in the FTY720-treated mice, and in vitro assays indicated that the regulatory function of these cells was enhanced. That FTY720 stimulation of Treg cells played a major role in arthritis inhibition was demonstrated by a loss of disease inhibition and restitution of the T-cell proliferative function after in vivo depletion of the Treg cells. CONCLUSIONS: While FTY720 affects the recirculation of lymphocytes, its ability to inhibit the development of autoimmune arthritis involves several mechanisms, including the enhancement of Treg cell function by increasing the Treg/Th ratio and increased regulatory function on a per-cell basis. FTY720 did not inhibit the development of the autoimmune T-cell response, but disease inhibition appeared to be mediated by Treg cell-mediated suppression of the CII-specific T cells. These data suggest that specific targeting of Treg cells with FTY720 may be a novel therapy for autoimmunity.
|
Authors | David C Miller, Karen B Whittington, David D Brand, Karen A Hasty, Edward F Rosloniec |
Journal | Arthritis research & therapy
(Arthritis Res Ther)
Vol. 18
Pg. 8
(Jan 12 2016)
ISSN: 1478-6362 [Electronic] England |
PMID | 26757712
(Publication Type: Journal Article, Research Support, U.S. Gov't, Non-P.H.S.)
|
Chemical References |
- Collagen Type II
- Immunosuppressive Agents
- Fingolimod Hydrochloride
|
Topics |
- Animals
- Arthritis, Experimental
(chemically induced, drug therapy, immunology)
- Autoimmune Diseases
(chemically induced, drug therapy, immunology)
- Autoimmunity
(drug effects, immunology)
- Collagen Type II
(toxicity)
- Fingolimod Hydrochloride
(pharmacology, therapeutic use)
- Humans
- Immunosuppressive Agents
(pharmacology, therapeutic use)
- Mice
- Mice, 129 Strain
- Mice, Inbred C57BL
- Mice, Transgenic
- T-Lymphocytes, Regulatory
(drug effects, immunology)
|